Blockchain Registration Transaction Record

Soligenix Advances Heat-Stable Ricin Vaccine with Promising Efficacy

Soligenix is developing RiVax, a heat-stable vaccine against ricin toxin, leveraging ThermoVax technology for no cold-chain storage, marking a biodefense breakthrough.

The development of RiVax by Soligenix represents a significant breakthrough in biodefense, offering a potential solution to one of the most lethal toxins known to humanity. Its heat-stable nature revolutionizes vaccine storage and distribution, making it accessible in remote or resource-limited settings. This advancement not only enhances global security against bioterrorism but also showcases the potential for innovative technologies to address critical public health challenges.